← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2544)
- Enhanced long-term outcomes with laparoscopic bariatric surgery in patients with severe obesity and metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study. (2026/06/01) ♡
- Targeting xCT-mediated amino acid metabolism: A novel mechanism of silymarin in ameliorating MAFLD-associated ferroptosis. (2026/06/01) ♡
- Kaempferol reprograms pro-inflammatory macrophage polarization by targeting the PTGS2-PGE(2) axis: A multi-omics deconvolution of a traditional anti-inflammatory herb pair. (2026/06/01) ♡
- Shugan Jiangzhuo Tablets mitigate non-alcoholic fatty liver disease by modulating TLR4/MyD88/NF-κB signaling pathway through gut microbiota. (2026/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mechanism of Action and Research Progress of Flavonoids From Traditional Chinese Medicine to Improve Metabolic Liver Disease. (2026/06/01) ♡
- Integrated analysis of network pharmacology and multi-omics reveals the mechanisms of Zuogui Jiangtang Qinggan formula ameliorates MASLD via fatty acid metabolic reprogramming. (2026/06/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Effect of TU-100 on Colorectal Liver Metastasis in Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. (2026/06/01) ♡
- Wu-Mei-Wan retards NAFLD progression by ameliorating obesity and regulating serum metabolites in high-fat diet-fed mice. (2026/06/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hypothyroidism in Nonalcoholic Fatty Liver Disease. (2026/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. TCM-Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD. (2026/06/01) ♡
- Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis. (2026/06/01) ♡
- Clinical characteristics of adolescents and young adults with type 2 diabetes and Traditional Chinese Medicine therapies: a single-center experience in China from 2011 to 2023. (2026/06/01) ♡
- [Comparative research on efficacy of high-pressure Schisandrae Chinensis Fructus decoction pieces and traditional decoction pieces on nonalcoholic fatty liver disease mice based on gut microbiota and metabolomics]. (2026/06/01) ♡
- [Single-cell RNA sequencing reveals the driving mechanism of CXCL9:SPP1 polarization in the progression of non-alcoholic fatty liver disease]. (2026/05/28) ♡
- [Associations of candidate gene polymorphisms, gut microbiota, and their interactions with NAFLD in obese children]. (2026/05/28) ♡
- Dendrobine ameliorates non-alcoholic fatty liver disease by inhibiting mitochondrial fission through modulation of the Wnt5a/p-CaMKII/p-Drp1 signaling axis. (2026/05/23) ♡
- Modulation of mRNA Expression of Biomarkers in the UPR-PERK Pathway by Ellagic Acid in Metabolic Dysfunction-Associated Fatty Liver Disease. (2026/05/17) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic potential of natural compounds from medicinal and food homology substances targeting gut microbiota in lipid metabolism disorders. (2026/05/15) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Shrimp peptides mitigate fatty liver-linked testicular dysfunction in rats via oxidative stress, autophagy, and energy pathways. (2026/05/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Benefit of Lycium barbarum polysaccharide supplementation in patients with nonalcoholic fatty liver disease: A pre-post study. (2026/05/01) ♡
- Environmental PET-microplastic exposure and risk of non-alcoholic fatty liver disease: An integrated computational toxicology and multi-omics study. (2026/05/01) ♡
- Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m(6)A modification. (2026/05/01) ♡
- Clinical efficacy of Jiawei Yinchenhao decoction combined with ursodeoxycholic acid and probiotics in the management of nonalcoholic fatty liver disease. (2026/05/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. (2026/05/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Establishment of a rat model of hepatointestinal injury induced by high-fat diet combined with dextran sulfate sodium]. (2026/05/01) ♡
- A prospective, randomized, controlled, open-label blinded end point clinical study of Ayulite in comparison with vitamin E for efficacy and safety in patients with non-alcoholic fatty liver disease. (2026/05/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. (2026/04/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Modulation of disease-associated gut microbiota by Schisandra chinensis: a literature review. (2026/04/17) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Traditional Chinese Medicine Modulation of the Gut-Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH. (2026/04/17) ♡
- Red yeast rice extract's impact on liver health: a pharmacological and metabolomic exploration. (2026/04/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A traditional herbal remedy in liver diseases: Momordica charantia L. (kudret narı/bitter melon). (2026/04/08) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis. (2026/04/02) ♡
- Identification of herbal formula Huatanqushihuoxue formula as a potential therapeutic agent for metabolism-related fatty liver disease: a multi-omics and network pharmacology approach. (2026/04/02) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Comparative Efficacy of Different Exercise Interventions on Intrahepatic Lipid Content, Glucose Homeostasis, and Liver Function in Adults With and Without Nonalcoholic Fatty Liver Disease: A Systematic Review With Pairwise and Network Meta-Analyses. (2026/04/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease. (2026/04/01) ♡
- Computational dissection through network pharmacology and structure-based analysis unravels mechanistic actions of bioactive compounds in a hepatoprotective herb, Picrorhiza kurroa for the treatment of NAFLD and NASH. (2026/04/01) ♡
- Bupleurum chinense ameliorates metabolic-associated fatty liver disease by modulating Sirtuin 6. (2026/04/01) ♡
- Nutrient-driven histone acetylation underlies energy storage and mobilization. (2026/04/01) ♡
- [Semaglutide and Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review]. (2026/03/31) ♡
- Taraxasterol from dandelion improves glycolipid metabolism dysfunction in diet-induced metabolic dysfunction-associated steatotic liver disease by modulating hepatic FXR. (2026/03/25) ♡
- Integrated Machine Learning and Multi-Omics Analysis Identifies Mitophagy-Related Core Genes and Mechanisms in Non-Alcoholic Fatty Liver Disease. (2026/03/24) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Daixie recipe ameliorates diet-induced MASH in mice via activating PI3K/AKT and Keap1/Nrf2 signaling. (2026/03/13) ♡
- Protective effects of a herbal combination (Dimocarpus longan and Orthosiphon stamineus) on metabolic-associated fatty liver disease via the ERα-PI3K-AKT pathway. (2026/03/09) ♡
- Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. (2026/03/07) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. An overview on phytotherapeutics for metabolic syndrome: A journey from traditional knowledge to modern clinical validation. (2026/03/06) ♡
- The CGA combination enhances bile acids alternative biosynthesis pathway and alleviates MASH induced by methionine-choline-deficient diet. (2026/03/05) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial. (2026/03/05) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Traditional Chinese medicine for type 2 diabetes with metabolic-associated steatotic liver disease: unified effects and design thresholds. (2026/03/03) ♡
- Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study. (2026/03/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Therapeutic potential of testosterone in hypogonadal males with MAFLD via AMPK pathways: Evidence from in vitro and in vivo high-fat diet models. (2026/03/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.